Glenda Gray
Perinatal HIV Research Unit
South Africa
About
No AI summary yet.
Metrics
- Publications
- 629
- Citations
- 28.6K
- h-index
- 80
- Publishing journals
- 223
- Years of publications
- 20+
- Active since
- 2007
- References
- 20.2K
- Institutions
- 78
Publication history
Latest publications
- A comparison of F/TAF and F/TDF as HIV pre-exposure prophylaxis in a predominantly cisgender women population in East and South Africa: a randomised, factorial, non-inferiority trial
- Strengthening the paediatric clinical trial ecosystem to better inform policy and programmes
- Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
- Evaluating the Test-Negative Design for COVID-19 Vaccine Effectiveness Using Randomized Trial Data: A Secondary Cross-Protocol Analysis of 5 Randomized Clinical Trials.
- An HIV Vaccine in the Era of Twice-Yearly Lenacapavir for PrEP — Essential or Irrelevant?
- Working at Cross-PURPOSEs to Ending HIV
- A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials
- Tenofovir Disoproxil Fumarate/Emtricitabine Prophylaxis Has No Effect on Bone Mineral Density and Bone Mineral Content in African Breastfeeding Women Receiving Pre-Exposure Prophylaxis for HIV
- The BRILLIANT HIV Vaccine Consortium: Unfunded but not undone
- Evaluation of pharmacokinetic interactions between long‐acting cabotegravir or emtricitabine/tenofovir disoproxil fumarate and hormonal contraceptive agents: a tertiary analysis of South African participants in HPTN 084
- Hybrid versus vaccine immunity of mRNA-1273 among people living with HIV in East and Southern Africa: a prospective cohort analysis from the multicentre CoVPN 3008 (Ubuntu) study
- Pre–Human Immunodeficiency Virus (HIV) α4β7hi CD4+ T Cells and HIV Risk Among Heterosexual Individuals in Africa
- Correction: A Risk Prediction Model to Identify People Living with HIV Who are High-risk for Disengagement from Care after HIV Diagnosis in South Africa.
- Corrigendum to ‘Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study’. EBioMedicine 2024;108: 105320
- SARS-CoV-2 vaccines elicit differential Fc effector functions
- Africa is an Essential Partner in the Research and Development of an HIV Vaccine.
- Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women
- Immune correlates analysis of antibody responses against SARS-CoV-2 variants in the ENSEMBLE vaccine efficacy trial
- Inflammatory cytokine biomarkers of asymptomatic sexually transmitted infections and vaginal dysbiosis: a multicentre validation study
- A Comparison of F/TAF and F/TDF as HIV Pre-Exposure Prophylaxis in a Predominantly Cisgender Women Population in East and South Africa: A Randomised, Factorial, Non-Inferiority Trial
No publications in the index yet.